Mesothelioma in New York

New York Mesothelioma Fact Sheet

While mesothelioma is a problem in all states, the specific incident rate for New York is 1 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in NY, recent NY mesothelioma-related court cases, mesothelioma specialists in NY and potential asbestos hotspots in New York.

[doptabs]
[doptab title=”Overview”]

New York Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of New York

New York Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

New York Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

New York Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

[/doptab]
[doptab title=”Treatment and Research”]

Research

[dopaccordions]
[dopaccordion title=”Chahinian, A Philippe. Predictive Chemotherapy For Malignant Mesothelioma
Grant: 1R01CA036283-01A1″ icon=27 activeicon=28]

Abstract:Malignant mesothelioma is a disease of growing importance. Its incidence is increasing as a result of the widespread use of its major etiologic agent, asbestos exposure, which is implicated in 70 to 80% of patients. The ubiquitous presence of asbestos, from schools to shipyards, has generated great public concern and awareness of this disease. Malignant mesothelioma is uniformly fatal, and neither surgery nor radiotherapy is curative. Very little information is available regarding the activity of chemotherapeutic agents. It is unlikely that empirical clinical trials will lead to any breakthrough in this disease. The availability at Mount Sinai of two distinct cell lines of human malignant mesothelioma serially transplanted into nude mice for over 4 years is unique. These two lines have retained the original pathological, histochemical and ultrastructural features despite serial transplantation. Karotypes have confirmed their human nature. This model will allow the screening of many classic and newer agents, alone and in combination, a task which would be impossible to conduct clinically even for cooperative groups, in view of the still relatively small number of patients with mesothelioma. An attempt at establishing new lines of mesothelioma representing the histologic spectrum of the disease (epithelial, mesenchymal and mixed) as well as different histochemical features, (high and low production of hyaluronic acid) will be investigated. Preliminary results in this nude mouse system have revealed that mitomycing C in one line, and cisplatin in the other one, were the most active single agents. The combination of mitomycin C and cisplatin, however, has been so far the most active regimen for both lines of human malignant mesothelioma xenografts in nude mice. Based entirely on these experiments, a clinical trial of mitomycin C and cisplatin for patients with malignant mesothelioma was begun at Mount Sinai, a referral center with probably the highest single institutional accrual for this disease in the United States. Initial clinical results of this combination strongly suggest that the nude mouse model does have predictive value in this system. The experimental nude mouse model, strengthened by the availability of an appropriate clinical setting, will allow further research to select regimens effective in nude mice bearing human mesothelioma xenografts, to correlate them with cell types and histochemical features, and to evaluate the most active ones in patients, in an effort to determine the predictiveness of the nude mouse model and to discover new effective therapies for mesothelioma.

Tags: Experimental Therapeutics Study Section, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Pharmacology, Neoplastic Therapy, Cancer Chemotherapy Antibiotics, Mitomycin C, Connective Tissue, Mesenchyme, Histochemistry And Cytochemistry (general), Metals, Heavy Metals, Platinum (compounds), Cis Platinum Compounds, Neoplastic Transformation, Carcinogens, Chemical, Polysaccharides, Glycosaminoglycans, Hyaluronic Acid, Silicates, Asbestos, Tissue (cell) Culture, Cell Culture Collections Banks And Registries, Tissue Compatibility-transplant, Transplantation Heterologous, Tissue, Epithelium Mammals, Rodents, Myomorpha, Athymic Mice (nude), Tissue (cell) Culture

Followup Grant: 5R01CA036283-02
Followup Grant: 5R01CA036283-03

[/dopaccordion]
[dopaccordion title=”Pass, Harvey I. Clinical Core Grant: 1P01CA114047-01A19001″ icon=27 activeicon=28]

Abstract:The Clinical Core housed at the Karmanos Cancer Institute is intended to be a resource for the program project as a whole and as a valuable source of biological materials necessary for the completion of the individual projects. The Clinical Core will be responsible for the collection, storage, and distribution of mesothelial cells and tissues, and mesothelioma tumors. The functions of the Clinical Core will be to serve as a resource for mesothelioma tumor tissue both snap frozen and paraffin embedded, and as a resource for asbestos-exposed pleura, lung, or peritoneum which is either snap frozen or paraffin embedded. The CORE will also serve as a resource for already established mesothelioma cell lines as well as an ongoing source of cultured human mesothelial cells from patients at the Karmanos Cancer Institute. New mesothelioma cell lines will be started prospectively from mesothleioma patients having resection. The Core will be responsible for the determining the SV40 status on these human mesothelial tissues, mesothelial cells, mesothelioma tumors and cultured mesothelioma cell lines in order to provide the appropriate reagents to the investigators. Tissue arrays for immunohistochemical validation of data will be constructed from paraffin embedded tumors and provided to the individual investigators. The Clinical Core will also coordinate the performance of asbestos lung content analysis from patients with mesothelioma for correlative data in the individual projects. It is estimated that 60-80 new mesothelioma cases per year will be seen at the Karmanos Cancer Institute during the course of the program project, and it is conservatively estimated that 20-30 of these will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used in Projects 1 and 3, and cell lines/cultures will be used in projects 2 and 3. By centralizing these services into a Core, the collection, storage, analysis, and distribution of tissues relevant to mesothelioma carcinogenesis will be better managed and coordinated for the entire Program Project.

Tags: Asbestos, Biomedical Facility, Environment Related Neoplasm /cancer, Mesothelioma, Tissue Resource /registry Gene Environment Interaction, Lung, Simian Virus 40 Cell Line, Human Tissue, Microarray Technology, Tissue /cell Culture, Tissue /cell Preparation

Followup Grant: 5P01CA114047-029001
Followup Grant: 5P01CA114047-039001

[/dopaccordion]
[dopaccordion title=”Suzuki, Yasunosuke Pathogenesis Of Experimental Malignant Mesothelioma Grant: 1R01CA024311-01A1″ icon=27 activeicon=28]

Abstract: An effective animal model exists that allows the production of peritoneal mesothelioma in rodents with asbestos and other inorganic fibers. We intend to use this model to investigate the pathogenesis of the disease and obtain data concerning the mechanisms involved, to help guide diagnosis and management of this increasingly important disease. Peritoneal mesothelium exposed to asbestos by either intraperitoneal or intra-abdominal wall administration will be studied in mice serially sacrificed. Investigations will include gross anatomy, histology, histochemistry, conventional electron microscopy, scanning electron microscopy and analytical electron microscopy. Questions to be investigated incude: 1) Is there any favorite site for the primary focus in the induced mesothelioma? (Parietal or visceral layer? Is there any specific location (such as the mesothelium directly covering lymphatic lacunea) to be identified?). 2) Structural and histochemical characterization of the mesothelioma cells at early stages of development. 3) The evolution of the mesothelium from normal to neoplastic. 4) Are abestos fibrils commonly and preferentially seen around the neoplastic mesothelium of the early stages? 5) Identification of floating mesothelioma cells in peritoneal effusions. 6) Response of mesothelioma upon transplantation into nude mice. 7) The comparative pathology of animal and human mesothelioma.

Tags: Neoplasms Of Body Cavities, Mesothelioma, Neoplastic Transformation, Carcinogenesis, Chemical, Pathology Study Section, Cell Differentiation Models, Biological, Neoplasms Diagnosis, Neoplasms Of Body Cavities, Peritoneal And Retroperitoneal, Neoplasms Related Interest, Preneoplastic Conditions, Neoplasms Transplantation, Neoplasms Vascular Supply, Tumor Angiogenesis Factor, Neoplasms, Environment Induced (ecologic) (general), Silicates, Asbestos Histochemistry And Cytochemistry (general), Histopathology (general), Human, Tissues, Fluids Etc. From Non-related Sources Outside Immediate Project, Mammals, Rodents, Myomorpha, Athymic Mice (nude), Mammals, Rodents, Myomorpha, Mice (laboratory), Optics, Microscopy, Electron, Optics, Microscopy, Electron Scanning, Optics, Microscopy, Phase

Followup Grant: 5R01CA024311-02
Followup Grant: 5R01CA024311-03

[/dopaccordion]
[dopaccordion title=”Suzuki, Yasunosuke Carcinogenic And Fibrogenic Effects Of Zeolites
Grant: 1R01CA029432-01″ icon=27 activeicon=28]

Abstract:We will investigate the pathological effects in mice of several zeolites by intraperitoneal injection of 10mg of four types of zeolites (2 fibrous erionites, mordenite, and non-fibrous zeolite). A single peritoneal injection will be utilized, followed by study after serial sacrifice or spontaneous death of the animals. Investigations will include gross anatomy, histology, histochemistry, and electron microscopy including transmission, scanning and high resolution analytical microscopy. Questions to be investigated include: (1) Do these zeolites induce malignant tumors? (2) If they do, are there differences in the neoplastic effects among them? (3) What kinds of malignant tumors are produced? (4) If malignant mesothelioma is produced — a) what is the pathogenetic process in its development? b) Are these explanations for the differences, if any, in the incidence of the mesothelioma production among the four zeolites? c) Is the histogenesis of malignant mesothelioma identical or similar for zeolites and asbestos? If there are differences, what are they? d) Are there features of zeolite-induced mesothelioma to allow differentiation from those induced by asbestos? (5) Do these zeolites induce fibroplastic effects? (6) How do the fibroplastic effects among the four zeolites differ? (7) Are “hyaline plaque formation” and pseudo-asbestos (“ferruginous”) body formation” seen in zeolite-induced fibrosis? (8) Is the process of the zeolite-induced fibrosis similar to that induced by asbestos? (9) Is fibrosis pathogenetically related to development of mesothelioma?

Tags: Chemical Pathology Study Section, Neoplastic Transformation, Carcinogenesis, Chemical, Neoplastic Transformation, Carcinogens, Chemical, Silicates Neoplasms Characteristics, Cellular Level Studies (general), Neoplasms Of Body Cavities, Mesothelioma, Neoplasms, Chemical Induced, Silicates, Asbestos Bioassay, Plaque Assay Techniques, Chemistry, Analytical Methods, Spectrometry, X-ray, Histochemistry And Cytochemistry (general), Histology (general), Mammals, Rodents, Myomorpha, Hamsters, Mammals, Rodents, Myomorpha, Mice (laboratory), Optics, Microscopy, Electron, Optics, Microscopy, Electron Scanning, Optics, Microscopy, Phase

Followup Grant: 5R01CA029432-02
Followup Grant: 5R01CA029432-03

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Relation Of Smoking To Neoplasia In Asbestos Workers
Grant: 5R01OH000320-11″ icon=27 activeicon=28]

Abstract:We have continued observation of the 17,800 men in the Asbestos Workers Union on January 1st, 1967, currently determining the status of each individual as of January 1st, 1976. 1,483.38 deaths were expected, 2,003 were recorded. The principal source of excess deaths was found in the cancer category; 281.49 such deaths were expected and 867 were found. In addition, there were 141 deaths of asbestosis. 51 deaths of pleural mesothelioma were seen and 93 of peritoneal mesothelioma. 92.28 deaths of lung cancer were expected and 427 were observed. There were also excess numbers of deaths of cancer of the larynx, oro-pharynx and kidney. These data reflect experiences in 150,950 man-years of observation. A number of significant observations are currently appearing. First, we are confirming the initial observation concerning the marked effect of asbestos exposure increasing the lung cancer risk of cigarette smoking; and that neither peritoneal nor pleural mesothelioma are associated. We are finding, too, that the risk of death of asbestosis is almost double for cigarette smokers, presumably adding bronchitis and emphysema to the asbestos interstitial fibrosis. We have also been analyzing excess deaths and have found that these increase beginning at 15 years from onset, reaching the extraordinary level of 43.7% of all deaths 40-44 years from onset being “excess.” We are also finding in a preliminary analysis, that cessation of cigarette smoking has an important effect in lowering the risk of death of lung cancer. 5-10 years after cessation of smoking, rates are approximately one third of those currently smoking. It is our intention to continue prospective surveillance of the remaining 15,797 workers alive on January 1st, 1976. BIBLIOGRAPHIC REFERENCES: Daum, S., Anderson, H.A., Lilis, R., Lorimer, W.V., Fischbein, A.S., Miller, A. and Selikoff, I.J. Pulmonary changes among titanium workers. Proc. Roy. Soc. Med. 70(1):31-32, 1977. (Abstract). Kannerstein, M., Churg, J., McCaughey, W.T.E. and Hill, D.P. Papillary tumors of peritoneum in women -mesothelioma or papillary carcinoma. Am. J. Obstet. Gynecol. 127(3):306-314, 1977.

Tags: Neoplastic Disease Epidemiology-statistics, Pathology Study Section, Psychology, Habits, Smoking, Silicates, Asbestos Neoplasms Immunology, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Gastrointestinal System, Neoplasms Of Respiratory System, Lung Neoplasms, Bronchogenic Carcinoma, Neoplasms Of Urinary Tract, Occupational Health, Occupational Hazards, Physical Properties, Particles, Dust, Population Studies Human, Longitudinal Study, Respiratory Disorders, Pneumoconiosis, Respiratory Disorders, Pulmonary Fibrosis And Granulomas Human, Clinical

Followup Grant: 5R01OH000320-12
Followup Grant: 2R01OH000320-08
Followup Grant: 5R01OH000320-10
Followup Grant: 5R01OH000320-07

[/dopaccordion]
[dopaccordion title=”Churg, Jacob Renal, Vascular And Pulmonary Structure In Disease
Grant: 5R01AM000918-22″ icon=27 activeicon=28]

Abstract:Experimental studies: Radiation effect on the testis will be studied by administering doses varying from 100 – 5,000 rads. Changes in the germinal cells, in the supporting cells, in the connective tissue and in blood vessels will be examined. Studies of radiation nephritis will be continued by administering moderate doses (1,500 – 2,000 rads) to an exteriorized kidney. Mesothelioma induced in hamsters by intrapleural administration of asbestos will be studied by light and electron microscopy and histochemically for the presence of acid mucopolysaccharides. Human renal diseases: Detailed morphological studies including electron microscopy and immunofluorescence microscopy will be conducted on renal biopsies and autopsy tissues and correlated with clinical and physiological changes. The following disease entities will be included: mesangio-capillary glomerulonephritis, primary and secondary amyloidosis, diabetes mellitus, toxic nephropathy and systemic lupus erythematosus. Structure of human mesothelioma, both peritoneal and pleural, will be examined by light and electron microscopy and by histochemical techniques and correlated with the clinical course and the outcome. Bibliographic references: Grishman, E. and Churg, J. Focal Glomerular Sclerosis in Nephrotic Patients: An Electron Microscopic Study of Glomerular Podocytes. Kidney International 7:111-122, 1975; Churg, J. Peritoneal Mesothelioma. Environ. Health Perspectives 9:317- 318, 1974.

Tags: Kidney Disorders, Metabolic Disorders, Neoplasms Of Body Cavities, Mesothelioma, Pathology Study Section Carbohydrates Metabolism Disorders, Diabetes, Connective Tissue Disorders, Lupus Erythematosus Systemic, Diseases, Cellular Level Studies (general), Human, Clinical, Immunopathology (general), Kidney Disorders, Glomerulonephritis, Kidney Disorders, Nephritis, Kidney Disorders, Nephrosclerosis, Kidney Disorders, Nephrosis, Kidney Disorders, Nephrotic Syndrome, Kidney, Glomerular Filtration, Kidney, Glomerulus, Membrane, Basement Membrane, Metabolic Disorders (inborn), Amyloidosis, Neoplasms Characteristics, Cellular Level Studies (general), Neoplastic Transformation, Carcinogens, Chemical, Radiation Effects, Reproductive System Male, Testis, Proteinuria Body Cavities, Serosa, Body Cavity Disorders, Peritoneal, Diagnostic Tests, Biopsy*, Histochemistry And Cytochemistry (general)*, Immunological Tests And Immunoassay, Immunofluorescence*, Kidney Disorders Diagnosis (incl Exams)*, Mammals, Rodents, Myomorpha, Mice (laboratory)*, Mammals, Rodents, Myomorpha, Rats (laboratory)*, Optics, Microscopy, Electron*

Followup Grant: 5R01AM000918-25
Followup Grant: 5R01AM000918-23
Followup Grant: 5R01AM000918-20
Followup Grant: 2R01AM000918-24

[/dopaccordion]
[dopaccordion title=”Pass, Harvey I. American/australian Mesothelioma Consortium
Grant: 5U01CA111295-03″ icon=27 activeicon=28]

Abstract:DESCRIPTION (provided by applicant): Malignant Pleural Mesothelioma (MM) is an asbestos-related malignancy which is detected at an advanced stage when curative options are not feasible. Sensitive and specific biomarkers which predict that an asbestos-exposed, high-risk-for-MM individual will develop MM do not exist. By combining the efforts of investigators in the United States and Australia at centers which are known for their expertise in bench work investigations and novel protocols for MM, a multifaceted approach for the rapid discovery and eventual validation of markers of early mesothelial carcinogenesis will be undertaken. This consortium will have the largest collection of reagents for biomarker discovery in MPM in the world, both as archived and prospectively collected specimens. The centers will be linked initially through the refinement of the potential mesothelial biomarker SMRP (soluble members of the mesothelin/Megakaryocyte Potentiating Factor related protein) building on already established industrial collaborations. Preliminary data reveals selective upregulation in sera and pleural effusions of MPM patients compared to other cancers and asbestos exposed individuals. Standards for the normal range of SMRP in asbestos exposed individuals will be established using an already existing >2000 patient Australian serum archive, and the positive/negative predictive value of the ELISA will be determined using existing and prospectively collected sera from MM patients. Both the US and Australian sites will also use the Affymetrix Expression Array Platform to define new soluble biomarkers by comparing non-cancerous mesothelium to early stage, resected mesothelioma tumors from the investigators archives. Preliminary data combining gene expression data with pathway analyses for secreted proteins suggests that osteopontin, MMP-3, and Cartilage Link Protein 1 could be promising markers for the detection of MPM. Further validation of these markers as well as the development of reagents for promising novel biomarkers will be performed at both the US and the Australian sites.

Tags: Asbestos, Biomarker, Mesothelioma Australia, Archive, Carcinogenesis, Cartilage, Exudate /transudate, Gene Expression, Link Protein, Megakaryocyte, Neoplasm /cancer, Osteopontin, Protein, Serum Clinical Research

Followup Grant: 1U01CA111295-01A1
Followup Grant: 5U01CA111295-02
Followup Grant: 3U01CA111295-03S1

[/dopaccordion]
[dopaccordion title=”Anderson, Henry A. Cancer Among Household Contacts Of Asbestos Workers
Grant: 1R01CA022792-01″ icon=27 activeicon=28]

Abstract:Cancer risk associated with exposure to asbestos is well established. The greatest risk is that suffered by workers; however, environmental exposure as in households of asbestos workers may also result in disease. While mesothelioma has been found among household contacts, quantitation of this risk has not been undertaken, nor is it known whether other asbestos-associated diseases (lung cancer, GI cancer) are also increased. In another study, we have established the mortality experience of a cohort of asbestos factory workers. In this investigation, we will study the mortality experience 1946-1980 of the family contacts of these asbestos factory workers, who resided in their households during the period of factory employment 1941-1945. Some data are available concerning the levels of their exposure. In a preliminary feasibility study, we have determined that the family cohort can be identified and traced, and that cause of death can be established for those who have died. Thus, it will be possible to evaluate the family contact experience in relation to an occupationally-exposed group, exposed to precisely the same fibers, from the same source, in the same years, in the same geographical area. Only the exposure circumstances and the intensity of exposure will have varied. It may be of interest that in the initial feasibility study, four cases of mesothelioma were found. Although three were alive when first discovered, all are now deceased, death having occurred approximately thirty years from onset of household exposure.

Tags: Epidemiology And Disease Control Study Section, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms, Cancer Data Systems, Neoplasms, Environment Induced (ecologic) (general), Neoplastic Disease Epidemiology-statistics, Cancer Risk, Neoplastic Transformation, Carcinogenesis, Chemical, Silicates, Asbestos, Family Occupational Health, Occupational Diseases, Population Studies Human, Mortality Human, Non-clinical

Followup Grant: 5R01CA022792-02
Followup Grant: 5R01CA022792-03

[/dopaccordion]
[dopaccordion title=”Chachoua, Abraham Cisplatin Analog In Malignant Pleural Mesothelioma
Grant: 5M01RR000096-390904″ icon=27 activeicon=28]

Abstract:Malignant pleural mesothelioma is a disease with a poor prognosis. This protocol attempts to improve local control of the disease by infusing the chemotherapeutic agent directly into the pleural space, thereby increasing local drug concentration, increasing exposure of the tumor to drug, and decreasing systemic toxicities of chemotherapeutic agents. The objectives of this phase II study of intrapleural liposomal entrapped cisplatin analog (L-NDDP) are to determine the antitumor efficacy, determine time to progression and survival, toxicity, and quality of life in patients receiving this therapy

Tags: Cis Platinum Compound, Drug Administration Route, Human Therapy Evaluation, Mesothelioma, Neoplasm /cancer Chemotherapy, Pleural Neoplasm Clinical Trial Phase Ii /iii /iv, Drug Screening /evaluation, Liposome Clinical Research, Human Subject

Followup Grant: 3M01RR000096-39S30904

[/dopaccordion]
[dopaccordion title=”Lebovits, Allen H. Controlled Psychologic Study Of Asbestos Exposure
Grant: 1R01ES002578-01″ icon=27 activeicon=28]

Abstract:Environmental oncogenic exposures are becoming increasingly more common. Phychosocial and emotional reactions to these exposures have not been extensively studied. Efforts have not been directed at assessing the impact of the information or at evaluating methods of conveying the information. Individuals who were exposed to asbestos 20-40 years ago are at an increased risk of developing neoplastic diseases, primarily mesothelioma and bronchogenic carcinoma. The study of this group at risk allows for the prospective examination of psychological factors, developmental and stressful events as potentially predictive of development of disease. This application proposes a psychological study of (1) men who were employed in asbestos work 20-40 years ago (N=150); (2) a control group of individuals without known oncogenic exposure (N=150) comparable in age, race, and socioeconomic level; (3) patients with mesothelioma (N=50). This study has three goals: 1) To assess the long-term psychological impact of the disclosure of oncogenic exposure. 2) To assess the subset of the group at risk who by virtue of continuing to smoke cigarettes, escalate their cancer risk. 3) To attempt to investigate the presence of potentially predictive psychological factors among a high-risk group as a feasibility study preparatory to a longitudinal prospective assessment. The psychological evaluation will focus on present and past psychological functioning, personality variables and constituency, developmental history, and stressful events for the past year. Specific reactions to high-risk knowledge and to onset of disease will also be assessed in the appropriate sample groups. Assessment methods will primarily rely on structured interviews and questionnaires. It is anticipated that results will be relevant for other oncogenic exposures as well and will be particularly significant for the construction of guidelines for the psychosocial management of oncogenically-exposed individuals.

Tags: Behavioral Medicine Study Section, Neoplasms Of Body Cavities, Mesothelioma, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Psychology, Attitude To Health And Health Problems, Silicates, Asbestos, Behavioral Medicine Health Records, Case History, Information Gathering (data Collection), Interviews, Information Gathering (data Collection), Questionnaires, Neoplasms, Chemical Induced, Neoplasms, Environment Induced (ecologic) (general), Neoplasms, Psychological Attributing Factors (general), Occupational Health, Occupational Hazards, Psychologic Stress, Psychological Adaptation, Coping Behavior, Psychological Tests, Behavior Assessment-measurement, Psychological Tests, Personality Assessment-measurement, Psychology, Habits, Smoking Human, Non-clinical

Followup Grant: 5R01ES002578-02
Followup Grant: 3R01ES002578-02S1
Followup Grant: 2R01ES002578-03
Followup Grant: 2R01ES002578-03

[/dopaccordion]
[dopaccordion title=”Fischbein, S Urinary Excretion Of Modified Nucleosides
Grant: 1R01OH002122-01″ icon=27 activeicon=28]

Abstract:Transfer RNA (tRNA) is a complex biomacromolecule containing a large number of modified bases. The modifications include methylation by several specific enzymes. These are hyperactive in malignant tumor tissue, which therefore contains tRNA that are different in structure form those present in normal tissue; they also have a high turnover rate. It is known that patients with cancer excrete in their urine elevated levels of such modified nucleosides (tumore markers). We have found abnormal levels of modified nucleosides in patients with asbestos related malignant mesothelioma, and we have shown in a feasibility study of individuals selected from the proposed study population but without clinical evidence of cancer tha asbestos insulation workers, with a history of long term exposure to asbestos and thus at high neoplastic risk, altered nucleoside excretion with appreciable prevalence. In the proposed investigation we will measure levels of modified nucleosides in the urine of 1,000 asbestos insulation workers with a history of 30 years or more from first onset of exposure. We will investigate whether the urinary excretion profile of nucleosides may be predictive of subsequent malignant disease One objective of the proposed study is therefore to investigate the usefulness of modified nucleoside levels in identifying individuals at high neoplastic risk. Extensive clinical and laboratory information is available on the proposed study population. The nucleoside pattern will be characterized for the entire population, and a matrix of intercorrelations between nucleosides and pertinent medical and laboratory information will be generated. Intra group differences will be evaluated for each nucleoside with respect to classification variables reflecting health affects of asbestos associated disease. The principal analysis of the proposed investigation will include prospective surveillance of all examined in terms of their mortality experience between 1984 and 1986. For this purpose we have developed a mechanism by which we will be made aware of the death of any individual in the study population. We will then study the association between the initial nucleoside excretion pattern and the mortality experience. Such information will provide important information about the significance of nucleoside levels and their capacity to serve as predictive markers for future malignant disease. Clarification of this may have important implications for prediction of occupational cancer.

Tags: Neoplasms Diagnosis, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Nucleosides, Occupational Health, Occupational Hazards, Safety And Occupational Health Study Section, Silicates, Asbestos, Urine Mathematics, Statistics (including Biometry), Neoplasms Of Body Cavities, Mesothelioma, Population Studies Human, Mortality Chemistry, Analytical Methods, Chemistry, Clinical, Urine Chemical Analysis, Human, Tissues, Fluids Etc. From Non-related Sources Outside Immediate Project, Physical Separation, Chromatography, Amino Acid Analyzer, Physical Separation, Chromatography, Reversed Phase Partition

Followup Grant: 5R01OH002122-02
Followup Grant: 5R01OH002122-03

[/dopaccordion]
[dopaccordion title=”Hamilton, John A. Environmental Dusts And Macrophage Activation
Grant: 1R01ES002014-01″ icon=27 activeicon=28]

Abstract:It has recently become apparent that the environmental component of cancer is more significant that generally imagined. We propose to test noxious dusts and fibers, which are commonly found in the environment, for their ability to induce putative inflammatory mediators from mouse peritoneal macrophages. These molecules are the enzymes, plasminogen activator and collagenase, and prostaglandins. Several environmentally important materials will be used with particular emphasis on asbestos. These fibers will be manipulated and physical measurements made to determine what structural and chemical characteristics are important for activity in our in vivo and in vitro test systems. We intend to study cellular control mechanisms for the synthesis of the mediators and hopefully to find drugs which could alleviate the deleterious effects of such fibers and dusts. We hope that our data may aid in the establishment of realistic control methods and standards for asbestos levels and the establishment of realistic control methods and standards for asbestos levels and types, as we will be placing emphasis on short asbestos fibers. It is also possible that our assays may be useful for detecting other harmful fibers and dusts in the environment. Because peritoneal mesotheliomas are a common form of mesothelioma in asbestos workers, we believe it relevant to be studying the interaction of asbestos with peritoneal cells.

Tags: Blood And Re System, Macrophages, Body Cavities, Peritoneum, Neoplasms, Environment Induced (ecologic) (general), Neoplastic Transformation, Carcinogenesis (general), Pathology Study Section, Physical And/or Chemical Agents Interaction (biological Andecological), Physical Properties, Particles, Dust Blood Coagulation, Fibrinolysis, Blood Coagulation, Plasminogen, Cell Types, Environmental Health, Sanitation And Control (general), Environmental Health, Wastes Industrial, Enzyme Mechanisms, Fatty Acids, Unsaturated, Prostaglandins, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Cavities, Peritoneal And Retroperitoneal, Proteases And Peptidases, Collagenase, Silicates, Asbestos, Toxicology, Environmental Hydrogen, Tritium, Immunological Tests And Immunoassay, Radioimmunoassay, Mammals, Rodents, Myomorpha, Mice (laboratory), Optics, Microscopy, Electron, Radioisotopes, Carbon, Radioisotopes, Iodine, Radiotracers, Tissue (cell) Culture

Followup Grant: 5R01ES002014-03

[/dopaccordion]
[dopaccordion title=”Prolonged Low Dose Topotecan Infusion Combined W/ Chest Irradiation
Grant:” icon=27 activeicon=28]

Abstract:

Tags: lture

Followup Grant: 5M01RR000096-390795
Followup Grant: 3M01RR000096-39S30795
Followup Grant: 5M01RR000096-400795
Followup Grant: 5M01RR000096-410795
Followup Grant: 5M01RR000096-420795

[/dopaccordion]
[dopaccordion title=”Cancer And Leukemia Group B
Grant:” icon=27 activeicon=28]

Abstract:

Tags: lture

Followup Grant: 5U10CA004457-35
Followup Grant: 5U10CA004457-36

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Shipyard Asbestos Disease: Mortality Experience
Grant: 5R01OH000682-03″ icon=27 activeicon=28]

Abstract:We are investigating the mortality experience of shipyard workers at a major coast shipyard, to ascertain whether their asbestos exposure will be associated with increased cancer mortality. A previous field survey of 1,000 current employees in the yard (Groton, Connecticut) showed a very high incidence of asbestosis in chest films, establishing that asbestos exposure had been common in the past. One thousand nine hundred and sixty men were employed in the yard on January 1, 1967 for at least ten years. By December 31, 1979, 340 were known to be deceased (17%) and 1,500 (76%) were known to be alive. Of these 830 (42%) were still employed in the shipyard. One hundred and twenty remained to be traced (6%). We expect to trace well over 95% of the cohort and will then analyze the mortality experience of the group, comparing expected deaths, based upon National Center for Health Statistics data for Connecticut and for the U.S. as a whole, with the differential experience of the various trades in the cohort (pipefitters, boilermakers, painters, carpenters, guards, foundry workers, electricians, machinists, etc.). We are also exploring the mortality experience of two additional cohorts in the same way; a ship repair yard in Baltimore, Maryland, and a new surface ship construction yard in Quincy, Massachusetts (the Connecticut yard constructs and repairs submarines). In each of the latter two, more than 2,000 workers comprise the cohorts. It will be of interest to compare the mortality experience with that of other asbestos-exposed workers (insulators, factory workers, miners and millers), with special reference to total mortality, lung cancer, pleural mesothelioma, peritoneal mexothelioma, gastrointestinal cancer, oropharyngeal and laryngeal cancer renal cancer and asbestosis. The statistical analysis will utilize both the death certificate enumeration and that following ascertainment, in comparing expected deaths with those observed.

Tags: Occupational Health, Occupational Diseases, Population Studies Human, Mortality, Respiratory Disorders, Pneumoconiosis, Safety And Occupational Health Study Section, Silicates, Asbestos Disease Proneness-risk, Geographical Sites, United States, Information Gathering Methods Evaluation-standards, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplastic Disease Epidemiology-statistics, Occupations, Industry, Population Studies Human, Epidemiology, Population Surveys Human, Clinical

Followup Grant: 5R01OH000682-02

[/dopaccordion]
[dopaccordion title=”Barcos, Maurice P. Cancer And Leukemia Group B Pathology
Grant: 2U10CA037055-05″ icon=27 activeicon=28]

Abstract:The major current objectives of the Pathology Committee of the Cancer and Leukemia Group B (CALGB) include: 1) provision of quality control in the histopathologic diangosis of various noeplasms in order to insure proper patient accession into protocols, 2) correlation of histologic classes of noeplasms with the incidence and duration of remission and overall survival, 3) correlation of cytologic types of leukemias and lymphomas with immunologic, cytogeneic, and molecular biologic markers, 4) study of malignant mesotheliomas by means of morphologic, histochemical and ultrastructural methods in order to classify and distinguish these neoplasms from other cancers, 5) determination of whether the fraction of cells in the S-phase of the proliferative cycle (S%), as determined by flow cytometry or 3H-thymidine, bromodeoxyuridine (BUdR) and Ki-67 labelling indices, provide independent prognostic information in patients with breast cancer, and 6) identification of long-term survivors with small cell lung cancer by means of a monoclonal antibody reagent (SCCL 175) which was developed against small cell carcinoma cells.

Tags: Immunological Preparations, Monoclonal Antibodies, Neoplasms Of Blood And Re System, Leukemia Acute, Neoplasms Of Reproductive System, Breast Neoplasms, Immunochemistry Cell Sorting, Laser, Diseases, Prognosis, Genetic Mapping, Genetic Markers, Genetics, Cytogenetics, Halopyrimidine Nucleosides, Halouracil Nucleosides, 5-bromodeoxyuridine, Neoplasms Characteristics, Cellular Level Studies, Neoplasms Diagnosis, Immunodiagnosis Of Neoplasms, Neoplasms Genetics, Neoplasms Immunology, Neoplasms Immunology, Tumor Antigens, Neoplasms Of Blood And Re System, Hodgkin’s Disease, Neoplasms Of Blood And Re System, Lymphoma, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Therapy Evaluation, Human, Viruses, Oncogenic Viruses, Mammary Tumor Viruses, Cell Division, Cell Growth Regulation, Cooperative Study, Histopathology Human, Clinical, Immunological Tests And Immunoassay, Radioimmunoassay, Radiotracers, Tissue (cell) Culture

Followup Grant: 5U10CA037055-06
Followup Grant: 5U10CA037055-07
Followup Grant: 5U10CA037055-08
Followup Grant: 5U10CA037055-09

[/dopaccordion]
[dopaccordion title=”Brandt-rauf, Paul W. P53 Biomaker And Intervention In Occupational Cancer
Grant: 1R01OH007590-01″ icon=27 activeicon=28]

Abstract:DESCRIPTION: Research Methods for Occupational Cancer are needed to develop early markers of adverse health effects from workplace exposures and to devise ways for interrupting the pathways between workplace exposures and resultant cancers. The p53 tumor suppressor gene product is a potential target for both of these approaches. Certain occupational exposures can produce mutations in p53 which cause the generation of an immune response with circulating p53 auto-antibodies, even before the occurrence of clinically detectable cancers, so that these antibodies may serve as useful early markers of adverse effects. In addition, certain short peptide sequences from p53 have been demonstrated in cell culture to be able to cause mutant p53 to revert to normal function, resulting in the death of cancer cells containing mutant p53 but with no effect on normal cells with wild-type p53, suggesting that this may be a useful approach for interrupting the pathway between workplace exposures that produce p53 mutations and resultant cancers. The purpose of the proposed research is to examine both of these approaches for occupational cancers caused by asbestos exposure in two related projects. For the first project, banked serum samples from a cohort of workers with asbestosis will be examined for the presence of p53 auto-antibodies by enzyme-linked immunosorbent assay and ininiunoblotting to determine if the presence of the antibodies correlates with the subsequent development of cancer, as well as with the presence of p53 mutations in the resultant tumors. For the second project, the effects in cell culture of a p53 peptide sequence (delivered as the peptide or as a plasmid-based mini-gene) on asbestos-associated lung cancer and mesothelioma cell lines with and without p53 mutations and corresponding non-cancer cell lines with wild-type p53 will be investigated, as well as determining the mechanism of action of the peptide for inducing death in these cells.

Tags: Asbestos, Autoantibody, Biomarker, Diagnosis Design /evaluation, Environment Related Neoplasm /cancer, Neoplasm /cancer Diagnosis, Occupational Disease /disorder, P53 Gene /protein Apoptosis, Comorbidity, Drug Screening /evaluation, Early Diagnosis, Gene Mutation, Neoplasm /cancer Epidemiology, Neoplastic Cell, Peptide Chemical Synthesis, Pneumoconiosis, Protein Sequence Clinical Research, Enzyme Linked Immunosorbent Assay, Human Tissue, Spectrometry, Tissue /cell Culture, Transfection /expression Vector, Western Blotting

Followup Grant: 5R01OH007590-02
Followup Grant: 5R01OH007590-03

[/dopaccordion]
[dopaccordion title=”Chahinian, A Philippe. Monocyte Chemotaxis In Cancer Patients
Grant: 1P01CA025865-010008″ icon=27 activeicon=28]

Abstract:

Tags: Blood Cells, Monocytes, Environment, Orientation, Chemotaxis, Therapy Evaluation Antibiotics, Anthracyclines, Adriamycin, Bacteria, Coryneform Group, Corynebacterium, Diseases, Prognosis, Drugs, Chemotherapy, Drugs Combination, Folic Acid Antagonists, Methotrexate, Haloalkylamines, Ccnu, Haloalkylamines, Cyclophosphamide, Hypersensitivity, Delayed Hypersensitivity, Imidazoles, Levamisole, Neoplasms Immunization (immunotherapy), Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Body Regions, Thoracic Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Surgery, Neoplastic Therapy, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Radioisotope (nuclear) Therapy, Neoplastic Therapy, Cancer Radiotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy Human, Clinical

Followup Grant: 5P01CA025865-020008
Followup Grant: 5P01CA025865-030008

[/dopaccordion]
[dopaccordion title=”Chu, Tsann Ming. Targeting And Therapy Of Tumors With Monoclonal Antibody
Grant: 5R01CA037646-05″ icon=27 activeicon=28]

Abstract:Monoclonal antibody F36/22 (IgG3, recognizes a glycoprotein with Mr of 700-1000K) has been shown immunohistochemically to be reactive with all human common epithelial ovarian cancers, while normal ovary expresses no detectable level of immunostain. Human exfoliated ovarian tumor cells are usually disseminating throughout the entire peritoneal cavity, and represent an ideal target for therapeutic manipulation in a confined compartment. A recently available human ovarian carcinoma xenograft in female athymic mice, NIH:OVCAR_3, expresses antigen recognized by monoclonal antibody F36/22 and resembles the human disease by producing ascites and intra-abdominal carcinomatosis. Using monoclonal antibody F36/22 as the probe and NIH:OVCAR-3 as the in vivo model, we will develop and eva;iate effective radioimmunotherapy for the targeting and elimination of peritoneal ovarian tumor seedings. Adriamycin, acommonly used cytotoxic agent in ovarian cancer, will be conjugated to monoclonal antibody F36/22 as the probe and NIH:OVCAR as the in vivo model, we will develop and evaluate effective radioimmunotherapy for the targeting and elimination of peritoneal ovarian tumor seedings. Adriamycin, a commonly used cytotoxic agent in ovarian cancer, will be conjugated to monoclonal antibody F36/22 for intracavity immunochemotherapy of ovarian tumor. Effectiveness of both therapies will be potentiated by biological response modifiers. The proposed approaches to the use of a unique monoclonal antibody in targeting and therapy of ovarian cancer in a confined cavity compartment with little or no communication with toher body compartments will generate defined and useful preclinical information.

Tags: Immunological Preparations, Monoclonal Antibodies, Neoplasms Characteristics, Molecular Level Studies, Neoplasms Immunization (immunotherapy), Neoplasms Immunology, Tumor Antigens, Neoplasms Of Reproductive System, Breast Neoplasms Antibiotics, Anthracyclines, Adriamycin, Antineoplastic Agents, Biological Response Modifiers, Immunity, Cellular, Cell Mediated Immune Responses, Antibody Dependent Cell Mediated Cytotoxicity, Immunology, Antibody Specificity, Neoplasms Diagnosis, Radioisotope Diagnosis, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Reproductive System Female, Ovary Neoplasms, Neoplasms, Adenocarcinoma, Neoplasms, Carcinoma, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Proteins, Glycoproteins, Therapy Evaluation, Human Animals, Chordates, Mammals, Rodents, Myomorpha, Athymic Mice (nude), Human, Human Tissues, Fluids Etc. From Non-related Sources Outside Immediate Pr Oject, Immunological Tests And Immunoassay, Radioimmunoassay, Neoplasms Resources, Registries, Radiotracers, Tissue (cell) Culture, Mixed Cultures, Tissue Compatibility-transplant, Transplantation Heterologous, Histopathology

[/dopaccordion]
[dopaccordion title=”Comis, Robert L. Phase I Study Of Talisomycin S10b
Grant: 2M01RR000229-200220″ icon=27 activeicon=28]

Abstract:

Tags:Antibiotics, Antineoplastic Antibiotics (general), Antibiotics, Bleomycin, Drugs Adverse Effects, Drugs, Pharmacology, Biochemical, Neoplastic Therapy, Cancer Chemotherapy Dosage And Route, Dosage, Drugs, Pharmacology, Bioavailability, Neoplasms Of Body Cavities, Mesothelioma Chemistry, Clinical, Blood, Chemistry, Clinical, Urine Chemical Analysis, Human, Clinical, Immunological Tests And Immunoassay, Radioimmunoassay

Followup Grant: 5M01RR000229-210220

[/dopaccordion]
[dopaccordion title=”Convit, Antonio Glucose Homeostasis In Aging
Grant: 5M01RR000096-390605″ icon=27 activeicon=28]

Abstract:This Phase I clinical trial attempts to determine the qualitative and quantitative toxicities of topotecan when given by prolonged infusion in combination with radiation therapy and their maximally tolerated dose in combination. It also attempts to document the degree of antitumor activity observed. Eligible tumor types, include but are not limited to, nonsmall cell lung, esophageal cancer, melanoma, mesothelioma, and thyroid cancer. The patients must be eligible for chest radiation.

Tags: Aging, Epidemiology, Glucose Metabolism, Homeostasis, Insulin Sensitivity /resistance Adrenocorticotropic Hormone, Cortisol, Hippocampus, Hormone Regulation /control Mechanism, Insulin, Memory Disorder Clinical Research, Electroencephalography, Glucose Tolerance Test, Human Subject, Magnetic Resonance Imaging, Neuropsychological Test

[/dopaccordion]
[dopaccordion title=”Feins, Richard H. Photodynamic Therapy For Malignant Mesothelioma
Grant: 2S07RR005403-290011″ icon=27 activeicon=28]

Abstract:

Tags:

[/dopaccordion]
[dopaccordion title=”Fisher, Susan G. A Comprehensive Investigation Of Viral-induced Lymphomagenesis
Grant: 5R01CA121180-02″ icon=27 activeicon=28]

Abstract:DESCRIPTION (provided by applicant): Non-Hodgkin’s lymphoma (NHL) incidence has increased dramatically in recent decades in the U.S. and worldwide. While this escalation has been considered almost epidemic in scope, the etiology of most subtypes of this heterogeneous group of malignancies remains elusive. Development of effective prevention and treatment strategies are highly unlikely without the identification of etiologic factors that contribute to development of this malignancy. The presence of simian virus 40 (SV40) has been reported in several human tumors, but the most common of these is NHL. Given existing evidence linking some specific subtypes of NHL to viral etiologies, a systematic and comprehensive assessment of the potential role of this virus in lymphomagenesis is warranted. The aims of this study are: to determine the prevalence of SV40 in tumors of B-cell origin as compared to normal lymph node specimens using sensitive, standardized detection techniques; to evaluate the role of SV-40 in lymphomagenesis; and to develop/optimize specific serologic tests for addressing viral transmissibility within familial clusters. This study will provide a comprehensive and objective assessment of the potential role of this virus in NHL. Regardless of the findings, this study will increase knowledge that will contribute to our understanding of the broader role of infectious pathogens in lymphoma. This will be the first study that addresses the potential association between SV40 and NHL with intentional recruitment of a representative sample of subjects (N=300) who undergo a comprehensive epidemiologic assessment, acquisition of specimens in a standardized fashion, and provision of evidence of tumorigenesis and complementary prevalence of antibody positivity. As demonstrated with other virally- induced tumors, such a conclusion would afford diverse opportunities for NHL prevention strategies specific to SV40 infection, i.e. vaccines (primary) or pharmacology therapy (secondary), and cancer control (tertiary), i.e. antiviral therapy or virus-targeted immunotherapy.

Tags:Neoplasm /cancer Dna, Polyomavirus, Active Immunization, Antibody, Antigen, Base, Cancer Risk, Capsid, Cell, Community, Conflict, Disease /disorder Prevention /control, Disease /disorder Proneness /risk, Disease Outbreak, Enzyme Linked Immunosorbent Assay, Ependymoma, Epidemiology, Gene, Health /scientific Organization, Human, Human Tissue, Immune Response, Immunization, Immunotherapy, Infection, Literature Survey, Lymph Node, Lymphatic Tissue, Lymphoma, Medicine, Mesothelioma, Model, Motivation, Oncology, Pharmacology, Poliomyelitis, Prevention, Role, Simian Virus 40, Success, Therapy, Tissue, Vaccine, Virus Clinical Research

Followup Grant: 5R01CA121180-03
Followup Grant: 5R01CA121180-04

[/dopaccordion]
[dopaccordion title=”Hei, Tom K. Mutagenicity Of Mineral Fibers
Grant: 2R01ES005786-05″ icon=27 activeicon=28]

Abstract:DESCRIPTION: (Adapted from the Investigator’s Abstract) Although asbestos is carcinogenic and induces both bronchogenic carcinomas and pleural and peritoneal mesotheliomas in humans, the underlying mechanisms of fiber carcinogenesis are not known. During the previous funding period, the applicant has shown, and for the first time, that asbestos fiber is a potent gene and chromosomal mutagen in mammalian cells and induce mostly large multilocus deletions. These findings provide the first direct link between chromosomal abnormalities that have frequently been demonstrated in vitro and carcinogenicity in vivo. To extend these findings and to examine how asbestos induces mutations, particularly the role of reactive oxygen species, the applicant proposes a series of seven specific aims to address three testable hypotheses using the human-hamster hybrid (AL) cell model. The first objective is to determine if oxyradicals, particularly hydroxyl radicals, generated by chrysotile asbestos result in oxidative DNA damages and mutagenesis in AL cells. The induction of the oxidative DNA damaged product, 8-hydroxl-2-‘deoxyguanosine and the formation of hydoxyl radicals will be determined from fiber-treated cultures using HPLC-EC and the salicylate assays respectively. To show that oxyradicals induced by chrysotile fibers actually mediate the mutagenic events, the incidence and types of SI mutants induced by equitoxic doses of either asbestos fibers or hydrogen peroxide (in vivo source of hydroxyl radicals) with or without concurrent treatment with antioxidant enzymes will also be determined. The second and third objective are to determine the role of intracellular glutathione levels and cellular phagocytic mechanism in modulating fiber mutagenesis. The AL cell line contains only one copy of human chromosome 11 and mutations at the S1 locus coded by the MICI gene located on 11p13 can be readily scored using an antibody complement lysis assay. By using specific DNA probes of other genes that have been regionally mapped to various sites on chromosome 11, the molecular spectrum of mutations induced by chrysotile fibers and oxyradicals will be compared.

Tags: Asbestos, Carcinogenesis, Free Radical Oxygen, Mutagen Testing Dna Damage, Enzyme Activity, Glutathione, Mesothelioma, Oxidative Stress, Physical State Cell Line, High Performance Liquid Chromatography, Human Genetic Material Tag, Hybrid Cell, Nucleic Acid Probe

Followup Grant: 5R01ES005786-06
Followup Grant: 5R01ES005786-07

[/dopaccordion]
[dopaccordion title=”Hilf, Russell Actions Of Hpd And Photoradiation Of Mammary Tumors
Grant: 2R01CA036856-09″ icon=27 activeicon=28]

Abstract:Photodynamic therapy (PDT) is a promising new cancer intervention that is based on the photoactivation of a systemically administered photosensitizing dye. Absorption of visible light by the dye results in the photosensitized formation of singlet oxygen (1O2) and subsequent cytotoxic reactions of 1O2 with cellular substrate. Considerable effort has been devoted to elucidate the mechanisms by which these photosensitized oxidations contribute to tumor destruction. These studies proposed here are designed to continue and extend our efforts, begun 10 years ago, to elucidate the biochemical basis for PDT-induced cytotoxicity and to use the new knowledge acquired in this effort to enhance the efficacy of the therapy. The proposed studies are interdisciplinary in nature, applying the expertise of scientists in biochemistry, biophysics, radiology and physics. Important new questions have arisen during the course of the previous grant period. Modifications in the photoradiation regimen have been shown to be capable of producing significant differences in inhibition of tumor growth. The mechanisms underlying these effects remain to be determined and experiments designed to accomplish this form an important focus for the proposed renewal. Different xenografts grown in the same host (nude mouse) possess significantly different sensitivities to PDT/ This finding has raised important questions concerning mechanism of action, sensitizer uptake and distribution, intrinsic differences between tumor cell types, etc. These studies will be pursued as will closely related problems in primary and transplanted rat mammary tumor models. Five specific aims have been formulated: (1) to optimize the drug and irradiation regimen in PDT of the R3230AC tumor in vivo and to quantitate an optimum therapeutic ratio in that system; (2) to determine sensitivities of primary and transplantable NMU tumors in the same host and to determine mechanisms differences in sensitivity between the R3230AC and the human mesothelioma xenograft in the nude mouse; (4) to perform several direct experimental tests in vitro and in vivo of the mechanisms whereby fractionated and reduced dose rate irradiation enhance the therapeutic response; and (5) to investigate the problem of recurrent tumors in PDT. In all of these studies, biochemical methods will be used in close conjunction with NMR imaging and spectroscopy, fluorescent probes, FACS, and radioactive labeling techniques.

Tags: Breast Neoplasm, Cellular Oncology, Neoplasm /cancer Photoradiation Therapy, Nonhuman Therapy Evaluation Neoplasm /cancer Transplantation, Nonvisual Photosensitivity, Oxygen Consumption, Radiation Dosage, Singlet Oxygen Athymic Mouse, Fluorescence Activated Cell Sorter, Fluorescent Dye /probe, Laboratory Rat, Nuclear Magnetic Resonance Spectroscopy, Radiotracer

[/dopaccordion]
[dopaccordion title=”Hilf, Russell Actions Of Photodynamic Therapy On Mammary Tumors
Grant: 5R01CA036856-10″ icon=27 activeicon=28]

Followup Grant: 5R01CA036856-11
Followup Grant: 5R01CA036856-12

[/dopaccordion]
[dopaccordion title=”Hilf, Russell Photodynamic Therapy Of Mammary Tumors
Grant: 2R01CA036856-14″ icon=27 activeicon=28]

Abstract:Approval of Photofrin for use in Photodynamic Therapy (PDT) of esophageal cancer provides impetus for development of optimal treatment regimens. Investigations from our laboratories have utilized numerous experimental models, including cultured cells, multicell spheroids, tumors in vivo and the in vivo-in vitro paradigm, to determine discrete sites of action of porphyrin-induced photosensitization. We determined that significant inhibition of inner mitochondrial enzymes led to marked reduction in ATP levels in cells and in tumors in situ, preceding tumor regression. By modeling oxygen diffusion and its photochemical consumption, irradiation schemes were devised that markedly improved tumor response. These models will be used to investigate, and then increase, the efficacy of delta- aminolevulinic acid (delta-ALA) induced photosensitization, a conceptually different approach to PDT. Delta-ALA induces the endogenous formation of the photosensitizer protoporphyrin IX (PPIX) via the heme biosynthetic pathway. We propose to determine localization of sensitization by measurement of site-specific enzyme response, alterations in components of the heme biosynthetic pathway and test for rate-limiting steps by using molecular biology techniques to transfect and overexpress selected enzymes. Multicell spheroids will provide a model to analyze spatial and temporal PPIX synthesis as it relates to metabolic status. Towards the goal of optimization of PDT, a stepped irradiation scheme, as well as irradiation of the tumor bed, will be applied to neoplasms in vivo. Mechanistic studies of vascular and metabolic responses to PDT in real time will be pursued in vivo using MR imaging and spectroscopy. Response of primary mammary tumors to PDT will determine whether lesions in situ differ in sensitivity from transplanted tumors. Results from these experiments will provide insight into discrete actions of delta-ALA- induced photosensitization and will form the basis for design of more effective PDT regimens for clinical use.

Tags: Breast Neoplasm, Mesothelioma, Neoplasm /cancer Photoradiation Therapy, Nonhuman Therapy Evaluation, Photosensitizing Agent, Porphyrin Aminohydrolase, Delta Aminolevulinate, Enzyme Activity, Hemoglobin, Porphobilinogen, Porphyrin Biosynthesis Athymic Mouse, Confocal Scanning Microscopy, High Performance Liquid Chromatography, Laboratory Rat, Nuclear Magnetic Resonance Spectroscopy, Tissue /cell Culture

Followup Grant: 3R01CA036856-15S1
Followup Grant: 5R01CA036856-16
Followup Grant: 3R01CA036856-16S1

[/dopaccordion]
[dopaccordion title=”Holland, James F. Cancer Center Support (core) Grant
Grant: 5P30CA023102-03″ icon=27 activeicon=28]

Abstract:The Specialized Cancer Center at Mount Sinai School of Medicine continues its work in immunologic diagnosis of breast cancer, analytical chemical diagnosis of fungal and bacterial infection and pathologic diagnosis of cells of interest by electronmicroscopy characteristics. Pharmacology of human cell lines in vitro in their native state and in the induced resistance state are conducted. Major emphasis has been placed on folic acid antagonists resistance and 2.4. diamminopyridine collateral sensitivity. Drug testing on human mesothelioma explanted into athymic mice continues. Investigation of electromagnetic radiation on chemotherapeutic effect on animal tumors is in progress. Clinical pharmacology of citrovorum and its modulation of 5-fluorouracil chemotherapeutic activity has begun. Controlled comparisons of cisplatin and doxorubicin versus cisplatin, doxorubicin and cyclophosphamide in ovarian cancer is in progress. A new trial comparing methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) versus MEPH (mitocycin, etoposide, cisplatin and hexamethylmelamine) followed by MACC offers a new lead in lung cancer, since MEPH has been recognized to demonstrate activity even after MACC failure. Studies of chemotherapy in an adjuvant setting of breast cancer and of colon cancer continues. Exploratory techniques of treating brain tumors have begun. Mathematical modeling of anticipated outcome has been progressively used to design regimens worthy of clinical tests. Such regimens, pioneered in the Cancer Center, have been extrapolated to Cooperative Study Groups for further implementation. The organizaion and interrelationships within the Cancer Center have significantly improved this past year, and a more cohesive effort across the entire Medical School is now evident. This application is submitted for continued support of the administration of the Cancer Center.

Tags: Biomedical Facilities, Cancer Center Support Grant Review Committee

Followup Grant: 3P30CA023102-03S1

[/dopaccordion]
[dopaccordion title=”Holland, James F. Cancer Center Support Grant
Grant: 2P30CA023102-04″ icon=27 activeicon=28]

Abstract: The Specialized Cancer Center at Mount Sinai School of Medicine continues its work in immunologic diagnosis of breast cancer, analytical chemical diagnosis of fungal and bacterial infection and pathologic diagnosis of cells of interest by electronmicroscopy characteristics. Pharmacology of human cell lines in vitro in their native state and in the induced resistance state are conducted. Major emphasis has been placed on folic acid antagonists resistance and 2.4. diamminopyridine collateral sensitivity. Drug testing on human mesothelioma explanted into athymic mice continues. Investigation of electromagnetic radiation on chemotherapeutic effect on animal tumors is in progress. Clinical pharmacology of citrovorum and its modulation of 5-fluorouracil chemotherapeutic activity has begun. Controlled comparisons of cisplatin and doxorubicin versus cisplatin, doxorubicin and cyclophosphamide in ovarian cancer is in progress. A new trial comparing methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) versus MEPH (mitocycin, etoposide, cisplatin and hexamethylmelamine) followed by MACC offers a new lead in lung cancer, since MEPH has been recognized to demonstrate activity even after MACC failure. Studies of chemotherapy in an adjuvant setting of breast cancer and of colon cancer continues. Exploratory techniques of treating brain tumors have begun. Mathematical modeling of anticipated outcome has been progressively used to design regimens worthy of clinical tests. Such regimens, pioneered in the Cancer Center, have been extrapolated to Cooperative Study Groups for further implementation. The organizaion and interrelationships within the Cancer Center have significantly improved this past year, and a more cohesive effort across the entire Medical School is now evident. This application is submitted for continued support of the administration of the Cancer Center.

Tags: Biomedical Facilities, Cancer Center Support Grant Review Committee

Followup Grant: 5P30CA023102-05
Followup Grant: 5P30CA023102-06
Followup Grant: 5P30CA023102-07
Followup Grant: 5P30CA023102-08
Followup Grant: 3P30CA023102-08S1

[/dopaccordion]
[dopaccordion title=”Langer, Arthur Laboratory Sciences–mineralogy
Grant: 2P30ES000928-11A19011″ icon=27 activeicon=28]

Abstract:

Tags: Biomedical Facilities, Chemicals (general), Minerals (general), Histopathology (general), Occupational Health, Occupational Diseases, Occupations, Industry, Physical And/or Chemical Agents Interaction (biological Andecological), Toxicants Interaction, Silicates, Asbestos Neoplasms Of Body Cavities, Mesothelioma, Neoplasms, Environment Induced (ecologic) (general), Physical Properties, Particles, Dust Death, Post-mortem, Human, Tissues, Fluids Etc. From Non-related Sources Outside Immediate Project, Optics, Microscopy, Electron, Toxicology, Environmental

Followup Grant: 5P30ES000928-129011
Followup Grant: 5P30ES000928-139011
Followup Grant: 2P30ES000928-149011

[/dopaccordion]
[dopaccordion title=”Levine, Ellis G. Cancer And Leukemia Group B–rpci/sunyab
Grant: 1U10CA059518-01″ icon=27 activeicon=28]

Abstract:Roswell Park Cancer Institute (RPCI) is requesting support to continue its participation in Cancer and Leukemia Group B (CALGB). For the past 3 years, since the arrival of Dr. Bloomfield, interim funding has been secured to allow RPCI to develop its present role in the Group. The goals of the CALGB participation include: (i) increased accrual to phase II/phase III clinical trials, based upon a steadily increasing patient recruitment since the reorganization of clinical services at RPCI; a particular emphasis will be placed upon solid tumor oncology and new drug development; (ii) increased investigator participation in CALGB activities, consequent upon a major program of recruitment; (iii) increased scientific contribution, based upon the application of selected aspects of our rapidly evolving translational research program to CALGB; (iv) increased attention to minority groups with the development of specific multimodality clinics for patients with esophagus and prostate cancer. Founded in 1898, Roswell Park Cancer Institute (RPCI) was one of the first institutions dedicated exclusively to the research and treatment of cancer and allied diseases. With more than 1400 staff, 200 beds, a large outpatient facility, and nearly 1,000,000 square feet of laboratory and hospital space provided by the State of New York, RPCI constitutes one of the 3 largest Cancer Centers in the United States, and was one of the first NCI-designated Comprehensive Cancer Centers. Under the direction of a team of senior investigators with major track records in clinical trial design and methodology and multidisciplinary management, the staff at RPCI and affiliates have increased accrual to CALGB trials from only 31 cases in 1988 to 162 in 1991, with a projected accrual of 200 in 1992. Increasing accrual has been seen at both the Main institution and at the affiliates, with a particular increase recently in solid tumor recruitment. RPCI also contributes substantially to the scientific, administrative, core, and publication activities of CALGB, as evidenced by the 60 protocols currently or recently chaired by staff members; the presence of the Offices of the Correlative Science, Cytogenetics and Pathology Committees and Flow Cytometry Core Facilities; active participation in Core Committees; authorship on 84 CALGB publications since 1988; and the completion of many early phase/pilot studies that have given rise to subsequent CALGB protocols. With the development of a new marrow transplant program and a new commitment to multidisciplinary management of solid tumors (augmented by a further increase in the intramural level of translational research, e.g., the current development of an extensive program of interactive laboratory research between the Departments of Medicine, Surgery, Flow Cytometry, Pathology and the Grace Cancer Drug Center targeted on mechanisms of response and resistance to treatment), a new level of scientific leadership will be available to CALGB as Roswell Park Cancer Institute completes its first century of cancer research.

Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Human Therapy Evaluation, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery B Lymphocyte, Hodgkin’s Disease, Acute Leukemia, Acute Myelogenous Leukemia, Acute Nonlymphocytic Leukemia, Alkylating Agent, Antineoplastic, Autologous Transplantation, Azacitidine, Bladder Neoplasm, Bone Marrow Transplantation, Breast Neoplasm, Cancer Registry /resource, Carmustine, Chromosome Translocation, Chronic Myelogenous Leukemia, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Daunorubicin, Deoxycoformycin, Doxorubicin, Drug Design /synthesis /production, Drug Resistance, Esophagus Neoplasm, Etoposide, Fluorouracil, Gastrointestinal Neoplasm, Gene Rearrangement, Hairy T Cell Leukemia, Ifosfamide, Immunoglobulin Gene, Interferon Alpha, Interferon Gamma, Interleukin 2, Interleukin 3, Leucovorin, Liposome, Lung Neoplasm, Lymphocytic Leukemia, Lymphoma, Melphalan, Mesothelioma, Minority Group, Mitomycin, Mitoxantrone, Monoclonal Antibody, Multiple Myeloma, Myelogenous Leukemia, Neoplasm /cancer Epidemiology, Neoplasm /cancer Genetics, Neoplasm /cancer Relapse /recurrence, Neoplasm /cancer Remission /regression, Nonhodgkin’s Lymphoma, Osteogenic Sarcoma, Prednisone, Prostate Neoplasm, Protooncogene, Somatostatin, Splenectomy, Transitional Cell Carcinoma, Trisomy Fluorescence Activated Cell Sorter, Human Subject, Polymerase Chain Reaction

Followup Grant: 5U10CA059518-02
Followup Grant: 5U10CA059518-03
Followup Grant: 5U10CA059518-05

[/dopaccordion]
[dopaccordion title=”Lippmann, Morton Effect Of Fiber Length On Asbestos Carcinogenicity
Grant: 1P01CA026724-010005″ icon=27 activeicon=28]

Abstract:

Tags: Diseases, Pathologic Processes, Irritation, Fibrosing Agents, Dosage And Route, Inhalation, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms, Environment Induced (ecologic) (general), Neoplastic Transformation, Carcinogenesis (general), Silicates, Asbestos Respiratory Disorders, Pneumoconiosis, Respiratory Disorders, Pulmonary Fibrosis And Granulomas, Respiratory Function Mammals, Rodents, Myomorpha, Rats (laboratory), Optics, Microscopy, Electron

Followup Grant: 5P01CA026724-020005
Followup Grant: 5P01CA026724-030005
Followup Grant: 5P01CA026724-040005
Followup Grant: 9P01ES003563-060005
Followup Grant: 5P01ES003563-070005
Followup Grant: 5P01ES003563-080005

[/dopaccordion]
[dopaccordion title=”Nicholson, William J. Epidemiology–mortality Studies
Grant: 2P30ES000928-11A19008″ icon=27 activeicon=28]

Abstract:

Tags: Biomedical Facilities, Neoplasms, Environment Induced (ecologic) (general), Neoplastic Disease Epidemiology-statistics, Cancer Risk, Occupational Health, Occupational Diseases, Occupations, Industry, Population Studies Human, Mortality, Toxicology, Environmental Amines, Nitrosamines, Haloolefins, Vinyledene Chloride, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Pancreas, Physical And/or Chemical Agents Interaction (biological Andecological), Toxicants Interaction, Plastics, Styrene Polymers, Psychology, Habits, Smoking, Silicates, Asbestos Human, Clinical

Followup Grant: 5P30ES000928-129008
Followup Grant: 5P30ES000928-139008
Followup Grant: 2P30ES000928-149008

[/dopaccordion]
[dopaccordion title=”Ohnuma, Takao In Vitro Chemotherapy And Chemoimmunotherapy
Grant: 1P01CA025865-010001″ icon=27 activeicon=28]

Abstract:

Tags: Drugs, Pharmacology, Biochemical, Neoplasms Immunization (immunotherapy), Neoplasms Pharmacology, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Combination Antineoplastic Therapy Albumins, Amidohydrolases, Asparaginase, Antibiotics, Anthracyclines, Blood And Re System, Lymphatic Tissue, Blood Cells, B Lymphocytes, Blood Cells, T Lymphocytes, Blood Proteins, Chemical Bonds, Binding, Dosage And Route, Route Of Administration, Drugs Resistance, Drugs Tolerance, Folic Acid Antagonists, Methotrexate Analogs, Models, Biological, Neoplasms Of Body Cavities, Mesothelioma, Neoplastic Cells, Pigment Cell Neoplasms, Melanoma, Protein Binding, Pyrimidine Nucleosides, Cytosine Nucleosides, Cytosine Arabinoside, Therapy Evaluation, Cell Differentiation, Cell Growth Regulation Blood And Re System, Hematopoietic Tissue, Tissue (cell) Culture, Tissue (cell) Culture, Cell Culture Collections Banks And Registries, Tissue (cell) Culture, Clone Cells

Followup Grant: 5P01CA025865-020001
Followup Grant: 5P01CA025865-030001

[/dopaccordion]
[dopaccordion title=”Rom, William Core–environmental And Occupational Medicine Program
Grant: 2P30ES000260-339012″ icon=27 activeicon=28]

Abstract:

Tags: Biomedical Facility, Environmental Health, Lung Disorder, Musculoskeletal Disorder, Occupational Disease Allergic Pneumonitis, Asthma, Biomechanics, Carpal Tunnel Syndrome, Cellular Pathology, Disease Proneness /risk, Epidemiology, Lung Neoplasm, Mesothelioma, Molecular Biology, Molecular Pathology, Pulmonary Fibrosis /granuloma, Tuberculosis Computed Axial Tomography, Diagnostic Respiratory Lavage, Electromyography, Human Subject

Followup Grant: 2P30ES000260-359012
Followup Grant: 5P30ES000260-369012
Followup Grant: 5P30ES000260-379012

[/dopaccordion]
[dopaccordion title=”Translational Research Training In Environmental Medicine
Grant:” icon=27 activeicon=28]

Followup Grant: 5T32ES007267-17
Followup Grant: 5T32ES007267-18

[/dopaccordion]
[dopaccordion title=”Ruckdeschel, John C. Lung Cancer Study Group
Grant: 5U10CA044074-03″ icon=27 activeicon=28]

Abstract:The purpose of this project is to continue the participation of Albany Medical College in the design and implementation of surgical adjuvant trials of the Lung Cancer Study Group (LCSG), to continue the accrual of patients to the active adjuvant studies of the LCSG and to continue follow-up on patients placed on the terminated studies of the LCSG in which Albany Medical College participated. There are five active adjuvant trials in non-small cell lung cancer (NSCLC) and one surgical consolidation study in SCLC. We will actively participate in the recently activated group wide pilot study of radical surgery in patients with Malignant Mesothelioma; LCSG 85Q. the Quality of life; the Natural History Catalog for T1NO patients not randomized preoperatively into the #821 protocol; the proposed Immunohistochemical Analysis of Lung Cancer study and LCSG 861, the trial of Intensive Intrapleural Chemotherapy for Malignant Pleural Effusions. Follow-up and data collection will continue for patients placed on inactive LCSG studies. New protocols are currently being planned for the management of thymoma and Pancoast tumors. Albany will continue to assist in the design and implementation of these trials. The recent activation of four major protocols will allow a further increase in our accrual so that we expect to accrue 55 patients in the 0-1 year, increasing to 75 patients per year by the fifth year subject to continued availability of active protocols.

Tags:Neoplasms Of Respiratory System, Lung Neoplasms, Neoplastic Therapy

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Asbestos Lung Burden In Environmental Mesothelioma
Grant: 1P10ES000928-010023″ icon=27 activeicon=28]

Abstract:

Tags: Environmental Health (general), Neoplasms, Silicates, Asbestos, Air Pollution Body Cavities, Serosa, Population Studies Human, Epidemiology, Respiratory System, Lung Histopathology (general)*, Human, Nonclinical*

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Mesothelioma In U.s. Shipyards
Grant: 1P10ES000928-010026″ icon=27 activeicon=28]

Abstract:

Tags: Neoplasms, Occupational Health, Occupational Diseases, Silicates, Asbestos, Air Pollution Body Cavities, Serosa, Population Studies Human, Epidemiology Human, Nonclinical*

[/dopaccordion]
[dopaccordion title=”Mesothelioma In New Jersey, 1973-1975
Grant:” icon=27 activeicon=28]

Abstract:

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Neoplastic Disease With Environmental Asbestos Exposure
Grant: 5P30ES000928-040045″ icon=27 activeicon=28]

Abstract:

Tags: Environmental Health, Contamination (general), Neoplasms, Environment Induced (ecologic) (general), Neoplastic Disease Epidemiology-statistics, Neoplastic Transformation, Carcinogenesis, Chemical, Occupations, Industry, Silicates, Asbestos Body Cavity Disorders, Pleural, Dyes, Food Sciences And Technology, Food Processing, Food Sciences And Technology, Food Sanitation, Food Contamination, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Gastrointestinal System, Neoplasms Of Respiratory System, Lung Neoplasms, Bronchogenic Carcinoma, Occupations, Industry, Mining, Physical Properties, Particles, Physical Properties, Particles, Dust, Plastics, Pvp, Population Studies Human, Longitudinal Study, Population Studies Human, Mortality, Respiratory Disorders, Envirnomental Pollutants Associated, Respiratory Disorders, Pneumoconiosis, Respiratory Disorders, Pulmonary Fibrosis And Granulomas, Silicates, Air Pollution Blood Cells, Erythrocytes, Hemolysis, Death, Post-mortem, Dosage And Route, Dosage, Histopathology (general)*, Human, Clinical, Mammals, Rodents, Myomorpha, Hamsters*, Optics, Microscopy, Electron*, Psychology, Habits, Smoking, Radiodiagnosis And Radiodiagnostic Methods, Socioenvironment, Urban Areas, Family

Followup Grant: 5P30ES000928-050045
Followup Grant: 2P30ES000928-060045
Followup Grant: 5P30ES000928-070045
Followup Grant: 5P30ES000928-080045
Followup Grant: 5P30ES000928-090045
Followup Grant: 5P30ES000928-100045
Followup Grant: 3P30ES000928-10S10045

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Biological Significance Of Ultramicroscopic Inorganic Particles
Grant: 5P30ES000928-080047″ icon=27 activeicon=28]

Abstract:

Tags: Chemicals (general), Minerals (general), Environmental Health, Contamination (general), Occupational Health, Occupational Diseases, Occupations, Industry, Physical Properties, Particles, Respiratory Disorders Epidemiology, Respiratory Disorders, Environmental Pollutants Associated, Toxicology, Poisoning Carbon, Coal, Consumer Products, Powder, Metal Oxides, Neoplasms Of Body Cavities, Mesothelioma, Physical Properties, Particles, Dust, Population Studies Human, Mortality, Respiratory Disorders, Pneumoconiosis, Respiratory Disorders, Pulmonary Fibrosis And Granulomas, Respiratory Disorders, Respiratory Airflow Disorders Chemistry, Analytical Methods, Spectrometry, Esr, Chemistry, Analytical Methods, X-ray Structure Analysis, Genetics, Mutagens, Mutagen Tests, Human, Clinical, Mammals, Rodents, Myomorpha, Mice (laboratory), Optics, Electron Optics, Optics, Microscopy, Electron, Respiratory Disorders Diagnosis, Respiratory Airflow Measurements, Respiratory Disorders Diagnosis, Spirometry, Tissue (cell) Culture

Followup Grant: 5P30ES000928-090047
Followup Grant: 5P30ES000928-100047
Followup Grant: 3P30ES000928-10S10047

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Environmental Cancer
Grant: 5P30ES000928-100043″ icon=27 activeicon=28]

Abstract:

Tags: Environmental Health, Contamination (general), Neoplasms, Environment Induced (ecologic) (general), Neoplastic Disease Epidemiology-statistics, Occupational Health, Occupational Diseases, Occupations, Industry, Plastics, Polyvinyls, Toxicology, Environmental Amines, Nitrosamines, Cyclics, Carbopolycyclics, Benzopyrenes, Immunity (and Natural Resistance) (general), Liver Disorders, Toxic Liver Disorders, Hepatotoxins, Metals Poisoning, Metals, Heavy Metals, Nickel (compounds), Neoplasms Of Biliary Tract, Liver Neoplasms, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Cardiovascular System, Angiosarcoma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Bronchogenic Carcinoma, Neoplasms Of Urinary Tract, Urinary Bladder Neoplasms, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Neoplastic Transformation, Carcinogens, Chemical, Physical And/or Chemical Agents Interaction (biological Andecological), Pollutants Interaction, Plastics, Styrene Polymers, Population Studies Human, Longitudinal Study, Population Studies Human, Mortality, Psychology, Habits, Smoking, Respiratory Disorders, Environmental Pollutants Associated, Silicates, Asbestos, Air Pollution, Pregnancy Immunology Air Sampling-monitoring, Chemistry, Analytical Methods, Spectrometry, Mass, Chemistry, Clinical, Urine Chemical Analysis, Genetics, Mutagens, Mutagen Tests, Human, Clinical, Optics, Microscopy, Electron

Followup Grant: 3P30ES000928-10S10043

[/dopaccordion]
[dopaccordion title=”Selikoff, Irving J. Lung Cancer: Prognostic Significance Of Vitamin A Levels
Grant: 1R01CA034296-01″ icon=27 activeicon=28]

Abstract:During 1982, we will determine the serum levels of vitamin A and beta-carotene in a large group of asbestos insulation workers (approximately 2,500). All will be at least 30 years from onset of their work. These men will be at very high risk of dying of lung cancer during the next 5 years. Experience has shown that 1 in 5 deaths will be of this disease (almost 1 in 2 will be of cancer of one or another site, including many of mesothelioma). Approximately one hundred deaths of lung cancer are anticipated. Following establishment of serum levels of vitamin A and beta-carotene, these men will be kept under prospective surveillance for the next five years, to determine whether their likelihood of dying of lung cancer is related to their preexisting serum levels of the substances. Evaluation will take into account other factors, including smoking and occupational histories, and demographic and medical status.

Tags: Neoplasms Diagnosis, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplastic Disease Epidemiology-statistics, Cancer Risk, Occupational Health, Occupational Diseases, Vitamins, Vitamin A (general) Diseases, Prognosis, Neoplasms Prevention And Control, Psychology, Habits, Smoking, Silicates, Asbestos, Vitamins Metabolism, Vitamins, Vitamin A, All-trans Retinol Chemistry, Clinical, Blood, Human, Clinical

Followup Grant: 5R01CA034296-02
Followup Grant: 5R01CA034296-03

[/dopaccordion]
[dopaccordion title=”Suzuki, Yasunosuke Laboratory Sciences–pathology
Grant: 2P30ES000928-11A19012″ icon=27 activeicon=28]

Abstract:

Tags: Biomedical Facilities, Histopathology (general), Neoplasms Of Body Cavities, Mesothelioma, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplasms, Chemical Induced, Neoplasms, Environment Induced (ecologic) (general), Occupational Health, Occupational Diseases, Occupations, Industry, Silicates, Asbestos, Toxicology, Environmental Histochemistry And Cytochemistry (general), Neoplasms Classification And Staging, Neoplasms Diagnosis, Physical And/or Chemical Agents Interaction (biological Andecological), Toxicants Interaction Death, Post-mortem, Diagnostic Tests, Biopsy, Human, Tissues, Fluids Etc. From Non-related Sources Outside Immediate Project, Optics, Microscopy, Electron

Followup Grant: 5P30ES000928-129012
Followup Grant: 5P30ES000928-139012
Followup Grant: 2P30ES000928-149012
Followup Grant: 5P30ES000928-169012
Followup Grant: 5P30ES000928-189012

[/dopaccordion]
[dopaccordion title=”Wiernik, Peter H. Eastern Cooperative Oncology Group
Grant: 5U10CA014958-08″ icon=27 activeicon=28]

Abstract:The Albert Einstein College of Medicine (AECOM) will continue to participate in the activities of the Eastern Cooperative Oncology Group. AECOM has been able to put about 100 patients per year on group-wide studies and current developments at AECOM should increase this accrual rate. The institution has been credited with the largest number of patients on approved ECOG pilot studies and between thirty and fifty patients per year are entered on these studies. Some of these approved pilot studies as well as in-house protocols have led to group-wide studies with investigators from AECOM serving as study chairmen. An in-house protocol in head and neck cancer led to the development of EST 1377 which compares a combination of methotrexate, bleomycin, and cis-platinum to methotrexate alone. Similarly, ECOG pilot studies PD 877, PC 877, and PD 878 for ovarian cancer led to EST 2878 and 2879, protocols studying various cis-platinum combinations in these patients. Phase II studies EST 2379 in head and neck cancer and EST 2877 in ovarian cancer are chaired by AECOM investigators. Studies in small cell cancer of the lung (1578) other lung cancer studies (2575, 2578) as well as a pending mesothelioma protocol also involve AECOM investigators. Finally, approved pilot studies in esophageal cancer, cervical cancer and breast cancer in addition to ovarian and head and neck studies are continuing. These studies have been made possible through the close interaction of the core of investigators at AECOM and a network of affiliated oncologists in the New York metropolitan area. The network’s activities are funded, in part, by a cancer control contract obtained through AECOM’s participation in ECOG activities.

Tags: Cancer Clinical Investigation Review Committee, Neoplastic Therapy, Cancer Chemotherapy, Neoplastic Therapy, Cancer Radiotherapy, Therapy Evaluation Antibiotics, Bleomycin, Diagnosis, Diagnostic Tests, Drugs, Chemotherapy, Drugs Combination, Drugs, Pharmacology, Biochemical, Education, Health Education, Cancer Education (prevention And Control), Folic Acid Antagonists, Methotrexate, Metals, Heavy Metals, Platinum (compounds), Cis Platinum Compounds, Neoplasms Classification And Staging, Neoplasms Diagnosis, Neoplasms Of Body Regions, Head And Neck, Neoplasms Of Gastrointestinal System, Esophagus Neoplasms, Neoplasms Of Reproductive System Female, Ovary Neoplasms, Neoplasms Of Reproductive System, Breast Neoplasms, Neoplasms Of Respiratory System, Lung Neoplasms, Neoplastic Therapy, Antineoplastic Agents, Neoplastic Therapy, Cancer Chemotherapy, Hormone Therapy, Neoplastic Therapy, Combination Antineoplastic Therapy, Cooperative Study Dosage And Route, Dosage, Human, Clinical

Followup Grant: 5U10CA014958-09
Followup Grant: 5U10CA014958-10

[/dopaccordion]
[/dopaccordions]

Clinical Trials

[dopaccordions]
[dopaccordion title=”Active, not recruiting Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma

Intervention: Drug: liposomal NDDP; Procedure: thoracoscopic surgery

More Information

[/dopaccordion]
[dopaccordion title=”Recruiting An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Drug: Milataxel
More Information

[/dopaccordion]
[dopaccordion title=”Completed Gefitinib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

[/dopaccordion]

[dopaccordion title=”Active, not recruiting Sorafenib in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: sorafenib tosylate
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Capecitabine in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

[/dopaccordion]
[dopaccordion title=”Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Alanosine in Treating Patients With Cancer” icon=27 activeicon=28]

Condition: Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Sarcoma
Intervention: Drug: L-alanosine
More Information

[/dopaccordion]
[dopaccordion title=”Completed Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: pemetrexed disodium
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)” icon=27 activeicon=28]

Condition: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Intervention: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
More Information

[/dopaccordion]
[dopaccordion title=”Completed Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: trabectedin
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin and Intensity Modulated Radiation Therapy
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Drug: Oxaliplatin/Gemcitabine
More Information

[/dopaccordion]
[dopaccordion title=”Completed Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Drug: Pemetrexed; Drug: Gemcitabine
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Neoadjuvant Pemetrexed Disodium and Cisplatin Followed by Surgery and Radiation Therapy in Treating Patients With Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: pemetrexed disodium; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
More Information

[/dopaccordion]
[dopaccordion title=”Active, not recruiting Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

[/dopaccordion]
[dopaccordion title=”Recruiting Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma” icon=27 activeicon=28]

Condition: Mesothelioma
Intervention: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
More Information

[/dopaccordion]
[dopaccordion title=”Completed Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma” icon=27 activeicon=28]

Condition: Leukemia; Lung Cancer; Malignant Mesothelioma; Myelodysplastic Syndromes; Peritoneal Cavity Cancer
Intervention: Biological: WT-1 analog peptide vaccine; Biological: incomplete Freund’s adjuvant; Biological: sargramostim; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunoenzyme technique
More Information

[/dopaccordion]

[/dopaccordions]
[/doptab]
[doptab title=”Doctors and Hospital”]

Hospitals and Cancer Centers

Memorial Sloan-Kettering Cancer

1275 York Ave.
New York, NY
212.639.2501

Regional Cancer Center

750 E. Adams
Syracuse, NY
315.464.8200

Roswell Park Cancer Institute

Elm and Carlton Streets
Buffalo, NY
877-275-7724

Physicians

Manjit Bains, M.D.
Memorial Sloan Kettering Cancer Center
1275 York Ave.
New York, NY 10021

Philippe A. Chihanian, M.D.
Mt. Sinai Hospital
5 East 98 St.
New York, NY 10029
(212) 241-6368

David Ilson, M.D.
Borys Mychalczak, M.D.
Sloan-Kettering Cancer Center
New York, NY

Nancy E. Kemeny, M.D.
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, NY 10065
(212) 639-8068

Dr. Valerie Rusch
Memorial Sloan-Kettering Cancer Center
1275 York Ave.
New York, NY 10021
(212) 639.5873
ruschv@mskcc.org

Harvey Pass, M.D.
NYU Medical Center
School of Medicine
530 First Ave.
New York, NY 10016
(212) 263-7300

Stephen Rush, M.D.
North Shore University Hospital
Manhasset, NY

Roman Perez-Soler, M.D.
New York University Kaplan Cancer Center
550 First Ave.
New York, NY 10016
(212) 263-8043
(212) 263-6485

Robert N. Taub, M.D.
Professor of Clinical Medicine, Program Director
Columbia-Presbyterian Hospital
Atchley Pavilion Room 907
161 Fort Washington Ave.
New York, NY

[/doptab]
[doptab title=”Cases”]

Holdampf v. A.C. & S., Inc. (In re New York City Asbestos Litig.)
No. 135 , COURT OF APPEALS OF NEW YORK, October 27, 2005, Decided
Charlop v. A.O. Smith Water Prods.
884N, 106190/07, SUPREME COURT OF NEW YORK, APPELLATE DIVISION, FIRST DEPARTMENT, July 21, 2009, Decided, July 21, 2009, Entered

Continental Cas. Co. v. Employers Ins. Co. of Wausau
601037/03, 2441, SUPREME COURT OF NEW YORK, APPELLATE DIVISION, FIRST DEPARTMENT, December 30, 2008, Decided, December 30, 2008, Entered

Matter of Lautenschuetz v. AP Greene Indus., Inc.
503455, SUPREME COURT OF NEW YORK, APPELLATE DIVISION, THIRD DEPARTMENT, February 21, 2008, Decided, February 21, 2008, Entered

Matter of New York Asbestos Litig. v. John Crane, Inc.
8246- 8246A, Index 119369/02, Index 106231/03 , SUPREME COURT OF NEW YORK, APPELLATE DIVISION, FIRST DEPARTMENT, April 11, 2006, Decided, April 11, 2006, Entered

Langhorne v. Amchem Prods., Inc.
7028-, 7029 , SUPREME COURT OF NEW YORK, APPELLATE DIVISION, FIRST DEPARTMENT, November 10, 2005, Decided, November 10, 2005, Entered

Cammarata v. Caldwell & Cook, Inc.
95491 , SUPREME COURT OF NEW YORK, APPELLATE DIVISION, THIRD DEPARTMENT, June 23, 2005, Decided, June 23, 2005, Entered

Cammarata v. Caldwell & Cook, Inc.
95489 , SUPREME COURT OF NEW YORK, APPELLATE DIVISION, THIRD DEPARTMENT, June 23, 2005, Decided, June 23, 2005, Entered

Root v. E. Refractories Co.
CA 04-01412 , SUPREME COURT OF NEW YORK, APPELLATE DIVISION, FOURTH DEPARTMENT, December 30, 2004, Decided , December 30, 2004, Entered

Lustenring v. AC&S, Inc.
4786, 4787 , SUPREME COURT OF NEW YORK, APPELLATE DIVISION, FIRST DEPARTMENT, December 2, 2004, Decided , December 2, 2004, Entered

[/doptab]
[doptab title=”Lawyers”]

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

Name*
State*
Email*
Phone
Name
This field is for validation purposes and should be left unchanged.

[/doptab]
[/doptabs]

1 (888) 378-1331

Mesothelioma in New York

New York Mesothelioma Fact Sheet

New York Mesothelioma Info

New York Research and Clinical Trials

New York Doctors and Hospitals

New York Cases

Research

Clinical Trials

Hospitals and Cancer Centers

Memorial Sloan-Kettering Cancer

Regional Cancer Center

Roswell Park Cancer Institute

Physicians

United States Sources

Centers for Disease Control and Prevention (CDC), UNITED STATES

Creighton University School of Medicine, UNITED STATES

David Geffen School of Medicine, UCLA, UNITED STATES

Icahn School of Medicine at Mount Sinai, New York, UNITED STATES

Mayo Clinic, UNITED STATES

Moffitt Cancer Center, Tampa, FL, UNITED STATES

National Institute for Occupational Safety & Health, UNITED STATES

University of Chicago, Medical Center, UNITED STATES

University of Maryland School of Medicine, UNITED STATES

University of Hawaii Cancer Center, UNITED STATES

Wake Forest University School of Medicine, UNITED STATES